Moreover, several MetAP2 inhibitors, such as fumagillin derivatives and newly developed reversible inhibitors, have demonstrated potential in preclinical and early clinical trials for obesity and T2DM. Here, METAP2 is linked to obesity due to melanocortin 4 receptor deficiency.